Physician profile
Jeffery A Guild
NPI 1598824369
$3,016.84
in general payments reported to CMS, 2019-2025
16 companies · $713 in 2025
The $713 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $36.77 · 2021: $33.59 · 2022: $473 · 2023: $369 · 2024: $796 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,878.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $592.98 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $461.72 | 2022-2024 | Miebo, Xiidra, Biotrue One Day |
| Abbvie INC. | $340.53 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $232.39 | 2019-2022 | |
| Glaukos Corporation | $184.76 | 2025 | Istent Infinite, Idosetr |
| Horizon Therapeutics Plc | $178.42 | 2023 | Tepezza |
| Allergan, INC. | $176.78 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $173.51 | 2019-2021 | |
| Alcon Vision LLC | $143.70 | 2023-2025 | Simbrinza, Rhopressa, Rocklatan |
| Aerie Pharmaceuticals, INC. | $139.26 | 2019 | |
| Rxsight INC | $124.71 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Coopervision INC. | $83.00 | 2019 | |
| Sun Pharmaceutical Industries INC. | $75.66 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $60.47 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $31.78 | 2023 | Tyrvaya |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $17.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffery Guild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.